Weight Loss & Metabolism
GLP-1 medications, metabolic health science, obesity medicine, and evidence-based weight management.
15 articles
Oral GLP-1 Pills Arrive: What Changes When the Needle Disappears
Oral formulations of GLP-1 medications are reaching pharmacy shelves in expanded doses, removing the biggest adoption barrier for needle-averse patients.
Aug 16, 2026
Mounjaro, Zepbound, and Beyond: Comparing the New Generation of Metabolic Drugs
With triple-hormone agonists like retatrutide posting record trial results, the metabolic drug pipeline is moving fast. Here's how the leading candidates compare.
Jul 15, 2026
GLP-1 Agonists for Weight Loss: Semaglutide, Tirzepatide, and the Future of Obesity Medicine
Comprehensive clinical review of GLP-1 receptor agonists — SURMOUNT and STEP trial results, mechanism of action, patient selection, monitoring, and what the obesity medicine landscape looks like post-approval.
Jun 28, 2026
Zepbound for Obstructive Sleep Apnea: How a Weight Loss Drug Is Transforming OSA Treatment
Tirzepatide (Zepbound) received FDA approval for obstructive sleep apnea in June 2024 — marking the first pharmacological approval for OSA. In 2026, the SURMOUNT-OSA data is reshaping how pulmonologists and sleep specialists approach the condition.
Jun 6, 2026
Retatrutide: The Triple Agonist That's Producing 24% Weight Loss — The Most Powerful Yet
Retatrutide (Eli Lilly) simultaneously activates GLP-1, GIP, and glucagon receptors — the first triple agonist in clinical development. Phase II data showing 24.2% weight loss at 48 weeks makes it the most potent anti-obesity agent ever tested. Phase III TRIUMPH trial results arrive in late 2026.
May 22, 2026
Ozempic & GLP-1 Weight Loss: What the Clinical Evidence Actually Shows in 2025
Beyond the headlines — evidence-based review of GLP-1 receptor agonists, metabolic benefits, risks, and what healthcare providers need to know about long-term use.
May 18, 2026
Compounded Peptides Under Scrutiny: What Patients Need to Know
With brand-name GLP-1 shortages easing, regulators are cracking down on compounded peptide alternatives. We break down the safety concerns and what's changed.
Mar 3, 2026
GLP-1 Weight Loss and Muscle Loss: How to Preserve Lean Mass on Semaglutide and Tirzepatide
Rapid weight loss on GLP-1 drugs can strip muscle along with fat. The evidence-based strategies — protein, resistance training, and monitoring — to protect lean mass.
Feb 13, 2026
After GLP-1: Why Weight Returns When You Stop and How to Maintain Loss
Studies show most weight returns after stopping GLP-1 medications. The physiology behind rebound and the realistic strategies for long-term maintenance.
Feb 11, 2026
Beyond Weight Loss: The Cardiovascular and Kidney Benefits of GLP-1 Drugs
GLP-1 medications reduce heart attacks, strokes, and kidney disease progression independent of weight loss. The expanding evidence reshaping who should take them.
Feb 9, 2026
Compounded GLP-1 Medications: Understanding the Safety Risks of Cheaper Alternatives
Compounded semaglutide and tirzepatide flooded the market during shortages. The real risks around dosing errors, purity, and regulation patients should understand.
Feb 7, 2026
Metabolic Adaptation: The Science of Weight Loss Plateaus and How to Break Them
Your metabolism adapts to defend against weight loss, causing frustrating plateaus. Understanding adaptive thermogenesis and the strategies that actually work.
Feb 5, 2026
Micro-Dosed GLP-1: The Maintenance-Dose Strategy Reshaping Weight Care
As millions of patients reach goal weight on GLP-1 therapy, clinicians are shifting focus to microdosed maintenance protocols designed to preserve results while minimizing side effects and cost.
Feb 2, 2026
The GLP-1 Weight Loss Revolution: Ozempic, Wegovy & the Future of Obesity Medicine
GLP-1 receptor agonists have redefined what's possible in weight management. New data shows 20%+ body weight reduction, cardiovascular benefits, and potential applications far beyond obesity.
Jun 5, 2025
Intermittent Fasting: The Updated Science on Weight, Metabolism & Longevity
New 2024–2025 research clarifies what intermittent fasting actually does to metabolism, insulin sensitivity, and cellular repair — and identifies who benefits most, and who should be cautious.
Mar 12, 2025Stock Your Facility with Clinical-Grade Supplies
400,000+ FDA-cleared products. Bulk pricing for healthcare facilities nationwide.